Eloxx Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview

Eloxx Pharmaceuticals

01/11/2021 17:58

* Eloxx Pharmaceuticals Inc  ELOX.OQ   ELOX.O  is expected
to show no change in quarterly revenue when it reports 
results on November 3 (estimated). 
​* Refinitiv's mean analyst estimate for Eloxx Pharmaceuticals
Inc is for a loss of 13 cents per share. For the same quarter
last year, the company reported a loss of 16 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $3.55​, about 61.4% above​ its last
closing price of $1.37. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.13       -0.14      -0.20     Missed  -45.5
 Mar. 312021   -0.16       -0.16      -0.22     Missed  -37.5
 Dec. 312020               -0.21      -0.15     Beat    30.2​
 Sep. 302020   -0.20       -0.19      -0.16     Beat    17.8
 ​​Jun.        -0.21       -0.21      -0.20     Beat    5.5
 302020                                                 
 Mar. 312020   -0.29       -0.30      -0.20     Beat    33​
 Dec. 312019   -0.32       -0.33      -0.29     Beat    10.9
 Sep. 302019   -0.39       -0.39      -0.32     Beat    18
 This summary was machine generated November 1 at 17:58 GMT.  All
figures in US dollars unless otherwise stated